Health

Philadelphia Nursing Home will close by the end of the year because of financial troubles, city officials said on Tuesday.

The expert panel agreed Tuesday that the vaccine made by Moderna is safe and effective enough to give to U.S. kids ages 6 to 17.

A new Penn study shows museums – in particular art museums – are good at reducing anxiety and depression.

Drexel University researchers call for reduced prescribing restrictions to persist after study finds people with opioid use disorder more likely to stay on their treatment.

MRIs done early for uncomplicated low back pain and routine vitamin D tests "just to be thorough" are considered "low-value care" and can lead to further costly testing.

Despite its legal status, delta-8 is not subject to any regulations or mandatory testing in Pennsylvania, and its packaging isn’t required to note potential side effects.

On Wednesday, the FDA will ask an independent panel of vaccine experts to debate both Pfizer's and Moderna’s vaccine data before voting.

Kids under 5 may be able to get the COVID-19 vaccine at the end of June. Pediatricians in the region explain what you need to know.

The founder of a midwifery clinic in Mississippi's capital is trying to open the state's first birth center.

Delaware set a new record for OD deaths in May. It’s the latest evidence that Delaware’s rate of overdose deaths shows no sign of slowing down.

The U.S. government is building up its supply of monkeypox vaccine to contend with escalating cases identified in a surprising international outbreak, health officials said.

A New Jersey company says its test can screen embryos for a variety of diseases and health conditions, like heart disease, diabetes, or breast cancer.

Since 2020, Pa. pharmacies have benefitted from emergency flexibilities, which allowed them to more easily vaccinate both adults and children. Those waivers are set to expire.

There are more than a dozen recalls related to last month's Jif peanut butter recall. Products from F&S Produce and Taharka Brothers have been added to the list.

The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate to have an effective booster ready for fall of 2022, the company said.